Trinity Biotech plc (TRIB)
NASDAQ: TRIB · Real-Time Price · USD
1.540
+0.060 (4.05%)
At close: Aug 28, 2025, 4:00 PM
1.500
-0.040 (-2.59%)
After-hours: Aug 28, 2025, 7:56 PM EDT
Trinity Biotech Revenue
In the year 2024, Trinity Biotech had annual revenue of $61.56M with 8.31% growth. Trinity Biotech had revenue of $15.86M in the quarter ending December 31, 2024.
Revenue (ttm)
$61.56M
Revenue Growth
+8.31%
P/S Ratio
0.09
Revenue / Employee
$153,504
Employees
401
Market Cap
5.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 61.56M | 4.72M | 8.31% |
| Dec 31, 2023 | 56.83M | -5.69M | -9.10% |
| Dec 31, 2022 | 62.52M | -18.63M | -22.96% |
| Dec 31, 2021 | 81.15M | -20.83M | -20.43% |
| Dec 31, 2020 | 101.98M | 11.55M | 12.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TRIB News
- 7 days ago - Trinity Biotech Appoints Paul Tivnan as Non-Executive Director - GlobeNewsWire
- 8 days ago - Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation - GlobeNewsWire
- 14 days ago - Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service - GlobeNewsWire
- 16 days ago - Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor - GlobeNewsWire
- 21 days ago - Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service - GlobeNewsWire
- 5 weeks ago - Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market - GlobeNewsWire
- 2 months ago - Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround - GlobeNewsWire
- 2 months ago - Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation - GlobeNewsWire